Abstract
Previous investigations of a Li – Fraumeni like family (Barnes et al., 1992) demonstrated that both the proband and her mother had elevated p53 protein levels in both tumour tissue and normal tissue at sites distant from the tumour, although no mutation was found in the p53 gene. In the present study two recently described functional assays for p53, an apoptotic assay and the functional assay for the separation of alleles in yeast (FASAY), have been employed to study the functional activity of p53 from this patient. The results of the apoptotic assay demonstrated that this patient had a p53 functional defect and the FASAY result suggested that this defect was in fact a germline mutation of the p53 gene. A point mutation of codon 337, which results in an amino acid substitution of a cysteine for an arginine, was demonstrated initially in cDNA and was confirmed by sequencing of genomic DNA. This is an unusual mutation as it is in the oligomerisation domain of p53, in contrast to the majority of p53 mutations which are in the core DNA binding domain. This mutation results in a protein which still retains partial transactivational activity in the FASAY. The mutation of codon 337 is only the second reported case of a germline missense mutation occurring in the oligomerisation domain of p53.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lomax, M., Barnes, D., Gilchrist, R. et al. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene 14, 1869–1874 (1997). https://doi.org/10.1038/sj.onc.1201133
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1201133
Keywords
This article is cited by
-
Programmed cell death detection methods: a systematic review and a categorical comparison
Apoptosis (2022)
-
The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report
BMC Cancer (2020)
-
TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database
Journal of Cancer Research and Clinical Oncology (2019)
-
The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer
Journal of Cancer Research and Clinical Oncology (2010)
-
Genotype Phenotype Correlation in Li-Fraumeni Syndrome Kindreds and its Implications for Management
Familial Cancer (2006)